EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome

Rasyidah Hasan Harahap, Riri Andri Muzasti, Alwi Thamrin Nasution

Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) · 2020

DOI: 10.32734/jetromi.v2i3.4293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI), 2020. Verfasst von Rasyidah Hasan Harahap und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Restless Legs Syndrome (RLS) is one of the most common sleep disturbance problems in dialysis patients. In this study, we would like to explore some of bone and mineral marker disorder especially fibroblast growth factor-23 (FGF-23)and its correlation with RLS in regular hemodialysis patients.

Methods

This is a cross sectional study design involving 71 respondents with chronic kidney disease that already had regular hemodialysis at Haji Adam Malik Hospital Medan. Status of RLS in this patients were being evaluated according to the International Restless Leg Syndrome Study Group (IRLSG) by interviewing and laboratory examination of FGF-23, hemoglobin (Hb), serum iron (SI), total iron binding capacity (TIBC), transferrin saturation (TSAT), serum ferritin, calcium (Ca) and phosphate (P) level.

Results

Of all study subjects, 26 respondents (34.6%) diagnosed with RLS. Bivariate analysis result showed that there is a relationship between FGF-23, hemoglobin, phosphate, and transferrin saturation level with RLS. Logistic regression analysis used to see the most dominant factor of all.

Conclusion

This study conclude that increase in FGF-23 levels can increase the risk of RLS. However, FGF-23 is not the most dominant risk factor for RLS in regular hemodialysis patients.

Zitieren

APA

Harahap, R. H., Muzasti, R. A., & Nasution, A. T. (2020). Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome. Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI). https://doi.org/10.32734/jetromi.v2i3.4293

Vancouver

Harahap RH, Muzasti RA, Nasution AT. Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome. Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI). 2020. doi:10.32734/jetromi.v2i3.4293

BibTeX
@article{Harahap2020,
  author = {Harahap, Rasyidah Hasan and Muzasti, Riri Andri and Nasution, Alwi Thamrin},
  title = {Fibroblast Growth Factor-23 (FGF-23) in Patients with Regular Hemodialysis: A Risk Factor for Restless Legs Syndrome},
  journal = {Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI)},
  year = {2020},
  doi = {10.32734/jetromi.v2i3.4293}
}
Kostenlos starten →